Interim PET after 4 cycles predicts outcome in histomolecularly confirmed primary mediastinal B-cell lymphoma

Interim PET after 4 cycles predicts outcome in histomolecularly confirmed primary mediastinal B-cell lymphoma

Abstract: The GAINED study was a randomized phase 3 trial comparing obinutuzumab (G) with rituximab (R) plus ACVBP (doxorubicin, cyclophosphamide, and prednisone, combined with either vindesine or bleomycin) or CHOP14 (cyclophosphamide, doxorubicin, vincristine, and prednisone, administered on a 14-...

Full description

Saved in:
Bibliographic Details
Main Authors: Vincent Camus, Thierry Molina, Fabienne Desmots, Paul Blanc-Durand, Salim Kanoun, Amine Moslemi, Philippe Ruminy, Steven Le Gouill, Hervé Ghesquières, Lucie Oberic, Franck Morschhauser, Hervé Tilly, Vincent Ribrag, Roch Houot, Catherine Thieblemont, Hervé Maisonneuve, Fabien Claves, Krimo Bouabdallah, Corinne Haioun, Gandhi Laurent Damaj, Luc-Matthieu Fornecker, Robin Noel, Pierre Feugier, David Sibon, Guillaume Cartron, Christophe Bonnet, Wivine Bernard, Françoise Kraeber-Bodéré, Caroline Bodet-Milin, Jean-Philippe Jais, Josette Brière, Cedric Rossi, Mad-Hélénie Elsensohn, Loïc Chartier, Emmanuel Itti, Fabrice Jardin, Thierry Fest
Format: Article
Language:English
Published: Elsevier 2025-05-01
Series:Blood Advances
Online Access:http://www.sciencedirect.com/science/article/pii/S2473952925001375
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2473952925001375

Similar Items